• A Novel Platform for Rapid Generation of Covalent Biotherapeutics (No. T4-2282)

    Covalent drugs have emerged as a groundbreaking modality for improving the affinity, potency, and duration of action of molecularly targeted inhibitors. Prof. ... Read more
    Senior Scientist Nir London

    Nir London

    Faculty of Chemistry

  • Adapters for Targeted Viral Vector-Based Therapies (No. T4-2229)

    A major challenge in developing viral-based therapies, such as gene therapies, CAR-T cell immunotherapy, and oncolytic virotherapy, is that the most efficient vectors and viruses are not specific, preventing their direct administration to the patient. Prof. ... Read more
    Prof Menachem Rubinstein

    Menachem Rubinstein

    Faculty of Biochemistry

  • A Novel Treatment for Cancer-Associated Cachexia (No. T4-2221)

    Cancer-associated cachexia (CAC) is a late-stage metabolic syndrome characterized by massive weight loss that occurs in 80% of cancer patients and is responsible for 20% of cancer deaths. It does not respond to dietary changes, and there is currently no effective biomarker or treatment for CAC. ... Read more
    Associate Professor Ayelet EREZ

    Ayelet Erez

    Faculty of Biology

  • An Improved Single-Cell RNA-Sequencing Method (No. T4-2217)

    Single-cell RNA sequencing (scRNA-seq) enables the analysis of gene expression in individual cells, unveiling new subsets of cells in different states or diseases through statistical analysis. ... Read more
    Prof Moshe Biton

    Moshe Biton

    Faculty of Biology

  • Hyperstable Serum Albumin Variants for Microbial Mass Production (No. T4-2216)

    Serum albumins are essential in a wide variety of molecular and cellular applications, including in the medical, biotechnological and cultivated meat industries. ... Read more
    Associate Professor Sarel FLEISHMAN

    Sarel-Jacob Fleishman

    Faculty of Biochemistry

  • High Throughput Screening Platform For Inhibitors of Viral Membrane Fusion (No. T4-2213)

    Enveloped viruses pose significant health risks and lack effective treatments. Inhibiting viral membrane fusion, a crucial step in infection, holds promise for antiviral drug development. Dr. ... Read more
    Prof Ori Porat Avinoam

    Ori Porat Avinoam

    Faculty of Biochemistry

  • Innovative Immunotherapy for Cardiac Regeneration after Myocardial Infarction (No. T4-2166)

    Myocardial infarction (MI), commonly known as a heart attack, is a leading cause of death worldwide, with no available therapies for restoring heart function post-MI. Prof. ... Read more
    Full Professor Eldad Tzahor

    Eldad Tzahor

    Faculty of Biology

  • Natural Human Antibodies to Treat Cancer (No. T4-2152)

    Ovarian cancer is the fifth leading cause of cancer-related death in women. Due to a lack of early detection methods, it is often diagnosed at a late stage, resulting in negligible changes to cure. ... Read more
    Full Professor Irit Sagi

    Irit Sagi

    Faculty of Biology

  • Treating myeloid malignancies with Rock inhibitors (No. T4-2147)

    Acute myeloid leukemia  (AML) incidents increases with age and mortality exceeds 90% when it is diagnosed after the age of 65. Specific mutations were shown to exist in pre-leukemic subjects years before the disease breaks. ... Read more
    Senior Scientist Liran Shlush

    Liran Shlush

    Faculty of Biology

  • Diagnosis and Treatment of Breast Cancer based on Extracellular Vesicles (No. T4-2145)

    Early detection of breast cancer (BC) and monitoring its progression, treatment response, and recurrence are crucial for survival. ... Read more
    Prof Sima Lev

    Sima Lev

    Faculty of Biology



Subscribe to Pharmaceuticals